Participated · Series A · Sep 2023

Lucid Scientific manufactures Resipher, a platform that converts standard cell culture plates into smart readers to detect and report metabolic changes in real time. Resipher provides researchers and drug discovery teams with actionable insights into cellular metabolism for therapeutic applications and drug safety. The company plans to use the new financing to expand production, sales and marketing, and to broaden new product advancements, including an upcoming launch of new Resipher hardware and consumable products this fall. Lucid is headquartered in Atlanta, GA and operates within the life‑science instruments market. Total funding to date is approximately $13 million following the Series A. IAG Venture Partner Dr. Ehsan Jabbarzadeh will join Lucid’s board as part of the financing. Lucid Scientific develops the patented RESIPHER system, which monitors cellular metabolism via non-invasive optical sensors and streams real-time data to researchers through a collaborative web platform. The RESIPHER system was originally developed at MIT and is intended to accelerate drug discovery and basic biological research. The company is led by president and CEO Dr. Walker Inman and is based in Atlanta, GA. Lucid plans to use new funding to expand production, sales and marketing, and to broaden product development. Financially, the company has raised a $3M seed round and has total funding to date of approximately $4.5M.

Participated · Series A · Nov 2022

Micron Biomedical develops a dissolvable microarray-based, needle-free platform for administration of drugs and vaccines. Its proprietary technology is designed to enable injection-free, painless and simple or self-administration, and to reduce or eliminate cold-chain requirements. The platform aims to enhance safety and efficacy while improving patient compliance. The company is led by CEO Steve Damon and is based in Atlanta, GA. Micron intends to use newly raised funds to expand operations and its R&D sector. Financially, the company extended its Series A to over $33M following the latest financing. Micron Biomedical is a clinical-stage life science company developing dissolvable microarray-based products for injection-free, painless administration of drugs and vaccines. Its core product is a microarray technology that reduces or eliminates cold chain requirements and enables community health workers to vaccinate quickly by applying a patch and pressing a button to confirm administration. Micron reported successful phase I/II clinical data in the Gambia across adults, toddlers, and infants as young as nine months using a leading commercial measles-rubella vaccine delivered via its microarray. The company plans to build a commercial-scale manufacturing facility—funded by a $23.6M Gates Foundation grant—to mass-produce needle-free vaccines and support larger clinical trials and regulatory approvals. Micron’s technology aims to expand vaccine access in low- and middle-income countries, improve patient acceptance in higher-income markets, and strengthen US national, veteran, and military health. Micron partners with the Bill & Melinda Gates Foundation, the CDC, PATH, and the Georgia Research Alliance and previously received a Gates grant in 2017 that enabled its first pediatric clinical trial. Micron Biomedical is an Atlanta-based life sciences company advancing dissolvable microarray-based drug and vaccine administration technology. Its patented microarray technology enables drugs and vaccines that today require cold storage and injection to be self-administered or caregiver-administered within minutes without refrigeration or a skilled health professional. The company aims to bring its dissolvable microarray products to markets globally. Micron has partnered with or received funding from private and public pharmaceutical and biotech companies as well as the Bill & Melinda Gates Foundation, the CDC, UNICEF, PATH and the Georgia Research Alliance. The company is led by CEO Steven Damon. The Series A extension will further support commercialization and global market efforts. Micron Biomedical is a clinical-stage life sciences company advancing its Micro Array Patch (MAP) technology to enable self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Led by CEO Steven Damon and based in Atlanta, GA, the company’s pipeline includes vaccine and drug products partnered with pharmaceutical companies, foundations, and government agencies. Micron has demonstrated clinical efficacy for its MAP technology and since inception has supported R&D with more than $40 million in non-dilutive financing. The company intends to use the new funds to develop commercial manufacturing capacity, which is currently underway. Micron has received support and funding from foundations and public health organizations that have partnered on development and trials.

Participated · Series A · Nov 2022

Nyra Medical develops the CARLEN transcatheter technology to treat mitral regurgitation. CARLEN is designed to preserve physiological valve geometry while restoring valve function, eliminate the risk of stenosis, and preserve a full range of future transcatheter and surgical treatment options. The company intends to use the financing to advance the technology through early feasibility clinical studies. Nyra was founded by Murali Padala and is based in Atlanta, GA. In conjunction with the financing the company added Lisa Wipperman Heine to its board as an independent director. The company raised $20M in a Series A financing.

Participated · Series A · Feb 2022

EarliTec Diagnostics is an Atlanta-based startup whose FDA-authorized system uses AI to track eye movements while a child watches short videos and social interactions to assist autism diagnosis. The tablet-based test takes about 12 minutes and targets children aged 16 to 30 months, aiming to shorten the multi-hour traditional assessment and reduce wait times. Its technology is currently used by eight clinicians across six U.S. states. The company raised new capital to expand commercialization and to fund research intended to broaden the age range it can assess and to improve assessment and treatment options. CEO Tom Ressemann emphasized the device’s flexibility to be used in clinics, schools, or at home so it can fit into existing workflows. The fresh funding will support those commercialization and research efforts. EarliTec Dx develops objective diagnostic and therapeutic products for children with Autism Spectrum Disorder using its EarliPoint® system and Dynamic Quantification of Social-Visual Engagement (DQSVE). The EarliPoint Evaluation is an investigational device that captures moment-by-moment looking behavior at 120 Hz while a child watches videos and compares each data point to a clinically validated database. The technology was developed with researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University, and the company has completed clinical trials with more than 1,500 children. EarliTec received FDA breakthrough designation for the EarliPoint system in April of last year. The company plans to seek FDA 510(k) clearance, commercialize the EarliPoint system, and expand its digital biomarkers built on a proprietary multimodal AI platform. A recent $19.5 million financing will fund regulatory filing, commercialization, and further development.

Participated · Series A · Nov 2018

Antios is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases, with a lead program targeting chronic HBV. Its lead candidate, ATI-2173, is a once-daily oral investigational phosphoramidate prodrug of clevudine monophosphate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development. ATI-2173 is in Phase 2b development and is being evaluated in the SAVE-1 trial, a double-blind, randomized, placebo-controlled study of 30 patients testing 25 mg and 50 mg doses daily for 90 days in combination with tenofovir disoproxil fumarate (TDF). Preclinical data and Phase 1b results indicate potent on-treatment and durable off-treatment HBV DNA suppression and that the drug has been generally well-tolerated. The company plans to advance ATI-2173 through Phase 2b and further clinical development toward a potential curative once-daily HBV regimen. The recent $75 million financing strengthens Antios's financial position to support these clinical programs. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases. Its lead candidate, ATI-2173, is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) designed to deliver the 5'-monophosphate of clevudine to the liver. ATI-2173 is described as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site, producing potent antiviral activity and extended off-treatment suppression of HBV DNA. The company plans to advance ATI-2173 through a Phase 2 clinical program to evaluate its potential as the backbone of a once-daily curative regimen for chronic hepatitis B. Antios reported potent on-treatment and durable off-treatment effects in a Phase 1b study, with those results slated for presentation at an upcoming medical conference. To support development, Antios completed a $96 million Series B financing. Antios Therapeutics is an Atlanta, GA–based biopharmaceutical company focused on developing novel antiviral therapies for unmet medical needs. Its lead oral candidate, ATI-2173, is being advanced as part of a curative regimen for chronic hepatitis B virus (HBV) and potentially hepatitis D virus (HDV). The company targets chronic HBV, which affects over 250 million people worldwide and is a leading cause of chronic hepatitis, liver cirrhosis and liver cancer. Antios is led by co-founders Abel De La Rosa (CEO) and Douglas Mayers (CMO). The company intends to use proceeds from its recent financing to continue development of ATI-2173. The article does not disclose revenue or user metrics.